UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained
UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained
瑞銀將阿里拉姆製藥的目標價從288美元上調至308美元，保持買入評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊